Ardelyx Inc. (ARDX)

2.37
0.13 5.20
NASDAQ : Health Technology
Prev Close 2.50
Open 2.50
Day Low/High 2.35 / 2.51
52 Wk Low/High 1.60 / 4.60
Volume 69.61K
Avg Volume 130.50K
Exchange NASDAQ
Shares Outstanding 62.60M
Market Cap 160.88M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.

This Market Action Is Not Creating Many Setups

This Market Action Is Not Creating Many Setups

Until market conditions shift, I won't be making any sizable buys.

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Ardelyx Has Big Potential

Ardelyx Has Big Potential

This small-cap company's shares are half where they ended 2015.

Profiting on Small-Cap Biotech Earnings

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.